Plasma levels of D-dimer and fibrin degradation product are unreliable for diagnosing periprosthetic joint infection in patients undergoing re-revision arthroplasty.


Journal

Journal of orthopaedic surgery and research
ISSN: 1749-799X
Titre abrégé: J Orthop Surg Res
Pays: England
ID NLM: 101265112

Informations de publication

Date de publication:
19 Oct 2021
Historique:
received: 16 08 2021
accepted: 30 09 2021
entrez: 20 10 2021
pubmed: 21 10 2021
medline: 28 1 2022
Statut: epublish

Résumé

The preoperative diagnosis of periprosthetic joint infection (PJI) in patients undergoing re-revision arthroplasty is crucial, so we evaluated whether plasma levels of D-dimer and fibrin degradation product (FDP) could aid such diagnosis. We retrospectively analyzed data on patients who underwent re-revision hip or knee arthroplasty at our institute during 2008-2020. Patients were stratified into those who experienced PJI or not, based on 2013 International Consensus Meeting Criteria. Plasma levels of D-dimer and FDP as well as levels of the traditional inflammatory biomarkers C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and interleukin-6 were compared between the groups. The ability of these biomarkers to diagnose PJI was assessed based on the area under the receiver operating characteristic (AUC) curve, for which predictive cut-offs were optimized based on the Youden index. Based on a cut-off of 0.80 mg/L, D-dimer gave an AUC of 0.595, high sensitivity of 85.7% but poor specificity of 47.8%. Based on a cut-off of 2.80 mg/L, FDP gave an AUC of 0.550, poor sensitivity of 56.5% and poor specificity of 52.9%. CRP, ESR and interleukin-6 showed much better diagnostic ability, with AUCs > 0.82. The combination of CRP and interleukin-6 gave an AUC of 0.877, high sensitivity of 91.7% and acceptable specificity of 78.3%. Plasma levels of D-dimer and FDP may be inappropriate for diagnosing PJI in patients undergoing re-revision arthroplasty, whereas the combination of serum CRP and interleukin-6 may be effective.

Sections du résumé

BACKGROUND BACKGROUND
The preoperative diagnosis of periprosthetic joint infection (PJI) in patients undergoing re-revision arthroplasty is crucial, so we evaluated whether plasma levels of D-dimer and fibrin degradation product (FDP) could aid such diagnosis.
METHODS METHODS
We retrospectively analyzed data on patients who underwent re-revision hip or knee arthroplasty at our institute during 2008-2020. Patients were stratified into those who experienced PJI or not, based on 2013 International Consensus Meeting Criteria. Plasma levels of D-dimer and FDP as well as levels of the traditional inflammatory biomarkers C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and interleukin-6 were compared between the groups. The ability of these biomarkers to diagnose PJI was assessed based on the area under the receiver operating characteristic (AUC) curve, for which predictive cut-offs were optimized based on the Youden index.
RESULTS RESULTS
Based on a cut-off of 0.80 mg/L, D-dimer gave an AUC of 0.595, high sensitivity of 85.7% but poor specificity of 47.8%. Based on a cut-off of 2.80 mg/L, FDP gave an AUC of 0.550, poor sensitivity of 56.5% and poor specificity of 52.9%. CRP, ESR and interleukin-6 showed much better diagnostic ability, with AUCs > 0.82. The combination of CRP and interleukin-6 gave an AUC of 0.877, high sensitivity of 91.7% and acceptable specificity of 78.3%.
CONCLUSIONS CONCLUSIONS
Plasma levels of D-dimer and FDP may be inappropriate for diagnosing PJI in patients undergoing re-revision arthroplasty, whereas the combination of serum CRP and interleukin-6 may be effective.

Identifiants

pubmed: 34666806
doi: 10.1186/s13018-021-02764-0
pii: 10.1186/s13018-021-02764-0
pmc: PMC8524877
doi:

Substances chimiques

Biomarkers 0
Fibrin Fibrinogen Degradation Products 0
Interleukin-6 0
fibrin fragment D 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

628

Subventions

Organisme : West China Hospital, Sichuan University
ID : ZYJC18039

Informations de copyright

© 2021. The Author(s).

Références

Int J Infect Dis. 2009 Nov;13(6):e444-9
pubmed: 19473865
Bone Joint Res. 2019 Sep 3;8(8):367-377
pubmed: 31537994
J Arthroplasty. 2018 May;33(5):1309-1314.e2
pubmed: 29551303
Arch Orthop Trauma Surg. 2021 May 15;:
pubmed: 33991236
BMJ Open. 2021 Jul 2;11(7):e046442
pubmed: 34215605
J Orthop. 2018 Aug 31;15(4):940-944
pubmed: 30202143
J Arthroplasty. 2021 Nov;36(11):3728-3733
pubmed: 34281702
Front Immunol. 2019 Nov 20;10:2699
pubmed: 31824494
J Orthop Sci. 2020 Oct 28;:
pubmed: 33127211
Orthop Surg. 2021 May;13(3):692-700
pubmed: 33682337
J Arthroplasty. 2021 Feb;36(2):693-699
pubmed: 32843254
Exp Ther Med. 2014 Jun;7(6):1573-1577
pubmed: 24926346
Minerva Pediatr (Torino). 2021 Apr 15;:
pubmed: 33858127
J Arthroplasty. 2017 Sep;32(9):2663-2668
pubmed: 28456561
J Arthroplasty. 2021 Aug;36(8):2962-2967
pubmed: 33814266
J Bone Joint Surg Am. 2017 Sep 6;99(17):1419-1427
pubmed: 28872523
J Arthroplasty. 2020 May;35(5):1361-1367
pubmed: 31899088
J Arthroplasty. 2021 Sep;36(9):3214-3220
pubmed: 33941413
J Arthroplasty. 2006 Feb;21(2):221-6
pubmed: 16520210
J Arthroplasty. 2021 Jul;36(7):2348-2352
pubmed: 33390338
J Arthroplasty. 2019 Oct;34(10):2454-2460
pubmed: 31155460
J Orthop Surg Res. 2019 Jul 29;14(1):240
pubmed: 31358018
J Arthroplasty. 2014 Jul;29(7):1331
pubmed: 24768547
Lancet. 2019 Feb 16;393(10172):655-663
pubmed: 30782341
Arthritis Rheum. 2002 Sep;46(9):2268-79
pubmed: 12355473
Health Care Manag (Frederick). 2011 Jul-Sep;30(3):227-35
pubmed: 21808174
Heart. 2021 Feb;107(3):195-200
pubmed: 33087410
Clin Orthop Relat Res. 2013 Jan;471(1):250-7
pubmed: 22552768
J Bone Joint Surg Am. 2014 Apr 2;96(7):536-42
pubmed: 24695919
Semin Thromb Hemost. 2020 Mar;46(2):176-182
pubmed: 32069515
J Orthop Surg Res. 2019 Nov 29;14(1):407
pubmed: 31783874
J Arthroplasty. 2020 Jun;35(6):1692-1695
pubmed: 32061477
Bone Joint J. 2021 Sep;103-B(9):1534-1540
pubmed: 34223770
J Bone Joint Surg Am. 2019 Apr 3;101(7):613-619
pubmed: 30946195
J Bone Joint Surg Am. 2007 Apr;89(4):780-5
pubmed: 17403800
J Orthop Surg Res. 2019 May 14;14(1):133
pubmed: 31088508
J Arthroplasty. 2021 Feb;36(2):e5
pubmed: 33187855
Int Orthop. 2017 Oct;41(10):2053-2059
pubmed: 28567578
JAMA. 2012 Sep 26;308(12):1227-36
pubmed: 23011713
Bone Joint J. 2020 Jun;102-B(6_Supple_A):138-144
pubmed: 32475286
J Orthop Surg Res. 2021 Jan 9;16(1):30
pubmed: 33422082

Auteurs

Hong Xu (H)

Department of Orthopaedic Surgery, West China Hospital, Sichuan University, No.37, Guoxue Road, Wuhou District, Chengdu, 610041, Sichuan, China.

Jinwei Xie (J)

Department of Orthopaedic Surgery, West China Hospital, Sichuan University, No.37, Guoxue Road, Wuhou District, Chengdu, 610041, Sichuan, China.

Duan Wang (D)

Department of Orthopaedic Surgery, West China Hospital, Sichuan University, No.37, Guoxue Road, Wuhou District, Chengdu, 610041, Sichuan, China.

Qiang Huang (Q)

Department of Orthopaedic Surgery, West China Hospital, Sichuan University, No.37, Guoxue Road, Wuhou District, Chengdu, 610041, Sichuan, China.

Zeyu Huang (Z)

Department of Orthopaedic Surgery, West China Hospital, Sichuan University, No.37, Guoxue Road, Wuhou District, Chengdu, 610041, Sichuan, China.

Zongke Zhou (Z)

Department of Orthopaedic Surgery, West China Hospital, Sichuan University, No.37, Guoxue Road, Wuhou District, Chengdu, 610041, Sichuan, China. zhouzongke@scu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH